Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. Key Points ...

The big pharma sector is one that’s generally fallen out of favor for many investors over the past few decades, as large ...

Novo Nordisk's (NVO) weight loss therapy Wegovy/Ozempic come out of shortage, but the FDA won't crack down on compounders ...

Many of these unlawful and unauthorized shipments were explicitly tagged for compounding, which in turn could put many ...

A doctor from the University of Palermo in Italy has published a case study of an adult cocaine user who experienced reduced withdrawal symptoms when given GLP-1 therapy. In the case study published ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Kwame Raoul is among several state AGs raising the alarm following complaints about online teleheath company Hims & Hers ...

Ozempic may also help people drink less alcohol. Primary care doctors are concerned about patients accessing GLP-1s through ...

Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.Across the 68 markets, sales ...

Hims & Hers is expanding its offerings through the Trybe Labs deal after it added compounded weight loss drugs.

ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control and adding savory flavors are ways that ...